A clinical trial of docetaxel plus cisplatin in treatment of advanced non-small cell lung cancer and breast cancer

Objective: The study was to evaluate the efficacy and tolerability of docetaxel plus cisplatin in the treatment of non-small cell lung cancer and breast cancer.Methods: Seventy-five patients were received docetaxel 70 mg/m² d₁ plus cisplatin 40 mg d_2-4,and the plan was repeated every 3 weeks.All the patients had to received at least 2 cycles of chemotherapy.Results: The response rate of the study(CR+PR) was 29.3%(non-small lung cancer was 27.9%,breast cancer was 31.3%).The main toxicities were myelo suppression,alimentary canal reactions,muscle soreness and fever,and the rate of grade Ⅳ was low.Conclusions: Docetaxel plus cisplatin can work effectively and safely in the treatment of advanced non-small lung cancer and breast cancer,and the toxicity can be toleranced.